4.6 Article

Shifting the Soil: Metformin Treatment Decreases the Protumorigenic Tumor Microenvironment in Epithelial Ovarian Cancer

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Immunology

Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors

Wenhui Liu et al.

Summary: Cancer poses a significant threat to public health, with ICIs ushering in a new era in clinical oncology and the potential for enhanced anticancer effects when combined with metformin. Studies have shown that metformin not only has beneficial effects on cancer prevention and treatment, but may also enhance the efficacy of ICIs through its impact on the host immune system.

FRONTIERS IN IMMUNOLOGY (2021)

Article Multidisciplinary Sciences

Cancer-associated MSC drive tumor immune exclusion and resistance to immunotherapy, which can be overcome by Hedgehog inhibition

Sandra Cascio et al.

Summary: CA-MSCs impact ovarian tumor immunity by secreting chemokines, driving CD8+ T cell exclusion, inhibiting NK cell activity, and polarizing macrophages. Hedgehog inhibitor therapy can reverse these effects, increasing intratumoral NK cell numbers and restoring response to ICI therapy.

SCIENCE ADVANCES (2021)

Article Oncology

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andres Poveda et al.

Summary: Olaparib provided a median overall survival benefit of 12.9 months compared with placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation. Although statistical significance was not reached, these findings are arguably clinically meaningful and support the use of maintenance olaparib in these patients.

LANCET ONCOLOGY (2021)

Article Oncology

Characterization of the Early Years of Bevacizumab Use for First-Line Treatment of Ovarian Cancer in the United States

Soledad Jorge et al.

Summary: The off-label use of bevacizumab for newly diagnosed ovarian cancer was rare in the United States, but doubled after the presentation of phase II and III data at international meetings. Both clinical factors (ascites, metastatic disease, age) and nonclinical factors (physician specialty and geographic region) were associated with the use of bevacizumab, which was accompanied by a sixfold increase in the cost of one cycle of treatment.

JCO ONCOLOGY PRACTICE (2021)

Article Multidisciplinary Sciences

B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma

Ayana T. Ruffin et al.

Summary: The study suggests that enhancing TIL-B responses in HNSCC, particularly in HPV+ cases, could complement current T cell immunotherapies. The presence of tumor infiltrating B cells with GCs in TLS is associated with better survival outcomes in head and neck squamous cell carcinoma patients.

NATURE COMMUNICATIONS (2021)

Article Medicine, Research & Experimental

Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer

Jason R. Brown et al.

JCI INSIGHT (2020)

Review Medicine, General & Internal

Epithelial ovarian cancer

Stephanie Lheureux et al.

LANCET (2019)

Review Medical Laboratory Technology

The double edge sword of fibrosis in cancer

Chelsea Chandler et al.

TRANSLATIONAL RESEARCH (2019)

Article Cell & Tissue Engineering

Ovarian Carcinoma-Associated Mesenchymal Stem Cells Arise from Tissue-Specific Normal Stroma

Lan G. Coffman et al.

STEM CELLS (2019)

Review Biochemistry & Molecular Biology

Anti-Cancer Effects of Metformin: Recent Evidences for its Role in Prevention and Treatment of Cancer

Masoumeh Kheirandish et al.

CURRENT DRUG METABOLISM (2018)

Review Endocrinology & Metabolism

Repurposing metformin for the prevention of cancer and cancer recurrence

Brandy M. Heckman-Stoddard et al.

DIABETOLOGIA (2017)

Article Biochemistry & Molecular Biology

Activation of AMP-activated Protein Kinase by Metformin Induces Protein Acetylation in Prostate and Ovarian Cancer Cells

Luciano Galdieri et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2016)

Article Obstetrics & Gynecology

Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models

Ernst Lengyel et al.

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2015)

Review Medicine, Research & Experimental

Metformin in Cancer Treatment and Prevention

Daniel R. Morales et al.

ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)

Article Oncology

Metformin targets ovarian cancer stem cells in vitro and in vivo

Jessica J. Shank et al.

GYNECOLOGIC ONCOLOGY (2012)

Article Biochemical Research Methods

NIH Image to ImageJ: 25 years of image analysis

Caroline A. Schneider et al.

NATURE METHODS (2012)

Article Cell Biology

Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner

R. Rattan et al.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2011)

Article Medicine, Research & Experimental

Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production

Karen McLean et al.

JOURNAL OF CLINICAL INVESTIGATION (2011)

Article Oncology

In vitro metformin anti-neoplastic activity in epithelial ovarian cancer

Walter H. Gotlieb et al.

GYNECOLOGIC ONCOLOGY (2008)

Article Multidisciplinary Sciences

Mesenchymal stem cells within tumour stroma promote breast cancer metastasis

Antoine E. Karnoub et al.

NATURE (2007)

Article Cell & Tissue Engineering

Immune regulation by mesenchymal stem cells derived from adult spleen and thymus

Mauro Krampera et al.

STEM CELLS AND DEVELOPMENT (2007)

Article Medicine, General & Internal

Metformin and reduced risk of cancer in diabetic patients

JMM Evans et al.

BMJ-BRITISH MEDICAL JOURNAL (2005)

Article Medicine, General & Internal

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

L Zhang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2003)